These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32909971)

  • 21. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
    Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.
    Costigan DC; Dong F; Nucci MR; Howitt BE
    Int J Gynecol Pathol; 2020 Mar; 39(2):119-127. PubMed ID: 30702464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Corded and hyalinized mesonephric-like adenocarcinoma of the uterine corpus: report of a case mimicking endometrioid carcinoma.
    Patel V; Kipp B; Schoolmeester JK
    Hum Pathol; 2019 Apr; 86():243-248. PubMed ID: 30172914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
    McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
    Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
    Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
    Huang HN; Kuo CW; Lin MC; Mao TL; Kuo KT
    Appl Immunohistochem Mol Morphol; 2020 Apr; 28(4):284-289. PubMed ID: 30789355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
    Xiong Y; Xiong YY; Zhou YF
    Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
    Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
    Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
    Schlosshauer PW; Ellenson LH; Soslow RA
    Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.
    Murali R; Davidson B; Fadare O; Carlson JA; Crum CP; Gilks CB; Irving JA; Malpica A; Matias-Guiu X; McCluggage WG; Mittal K; Oliva E; Parkash V; Rutgers JKL; Staats PN; Stewart CJR; Tornos C; Soslow RA
    Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S40-S63. PubMed ID: 30550483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic features and genomic analysis of pulmonary blastomatoid carcinosarcoma.
    Zhao J; Xiang C; Zhao R; Guo P; Zheng J; Han-Zhang H; Yu K; Zhang J; Han Y
    BMC Cancer; 2020 Mar; 20(1):248. PubMed ID: 32209061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endometrial serous carcinoma with a corded and hyalinized pattern: a clinicopathological and molecular analysis.
    Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Piermattei A; Onori ME; Minucci A; Pedone Anchora L; Fanfani F; Zannoni GF
    Pathologica; 2024 Jun; 116(3):176-179. PubMed ID: 38979592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low grade endometrial endometrioid adenocarcinoma: A review and update with emphasis on morphologic variants, mimics, immunohistochemical and molecular features.
    Lucas E; Carrick KS
    Semin Diagn Pathol; 2022 May; 39(3):159-175. PubMed ID: 35397943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Un- and dedifferentiated endometrial carcinoma : A rare entity with a wide range of differential diagnosis].
    Höhn AK; Brambs CE; Opitz S; Erber R; Hartmann A; Horn LC
    Pathologe; 2019 Nov; 40(6):609-618. PubMed ID: 31578630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant.
    Strehl JD; Wachter DL; Fiedler J; Heimerl E; Beckmann MW; Hartmann A; Agaimy A
    Ann Diagn Pathol; 2015 Aug; 19(4):198-202. PubMed ID: 25920939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
    Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
    Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.